Search details
1.
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
Invest New Drugs
; 31(4): 1035-43, 2013 Aug.
Article
in English
| MEDLINE | ID: mdl-23417697
2.
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Support Care Cancer
; 21(6): 1691-5, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23314653
3.
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Curr Oncol
; 30(6): 5456-5469, 2023 06 04.
Article
in English
| MEDLINE | ID: mdl-37366896
4.
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
Cancers (Basel)
; 15(24)2023 Dec 08.
Article
in English
| MEDLINE | ID: mdl-38136304
5.
Symptom improvement as prognostic factor for survival in cancer patients undergoing palliative care: a pilot study.
Support Care Cancer
; 20(6): 1221-6, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-21688165
6.
Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Anticancer Res
; 41(5): 2553-2561, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33952483
7.
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Breast J
; 16(1): 66-72, 2010.
Article
in English
| MEDLINE | ID: mdl-19889170
8.
Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study.
Tumori
; 105(3): 243-252, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-30857495
9.
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Eur J Cancer
; 109: 175-182, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30735919
10.
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
JAMA Oncol
; 4(4): 529-536, 2018 Apr 01.
Article
in English
| MEDLINE | ID: mdl-29450468
11.
Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.
PLoS One
; 11(7): e0157751, 2016.
Article
in English
| MEDLINE | ID: mdl-27442239
12.
Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?
Springerplus
; 2(1): 185, 2013 Dec.
Article
in English
| MEDLINE | ID: mdl-23667824
13.
Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis.
PLoS One
; 8(12): e80188, 2013.
Article
in English
| MEDLINE | ID: mdl-24339871
Results
1 -
13
de 13
1
Next >
>>